APL-2, a Complement C3 Inhibitor, May Potentially Reduce Both Intravascular and Extravascular Hemolysis in Patients With Paroxysmal Nocturnal Hemoglobinuria (EMCHD 2017) - Apellis Medical Hub

APL-2, a Complement C3 Inhibitor, May Potentially Reduce Both Intravascular and Extravascular Hemolysis in Patients With Paroxysmal Nocturnal Hemoglobinuria

Share Via Email

Back to Conference Resources

PNH Congress Presentations European Meeting on Complement in Human Disease (EMCHD) 2017

The following information is available for educational purposes only. The information is not to be re-purposed or re-used in its current form or presentation for any personal or professional use. Apellis reserves the right to withdraw, modify or change the information that is available on this website at any time.